Genome Editing Market Expected to Witness a CAGR of 14.4% to Reach $8.3 Billion by 2025 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 26, 2019--The “Global Genome Editing Market - Drivers, Restraints, Opportunities, Trends, and Forecast, 2019-2025” report has been added to ResearchAndMarkets.com’s offering.
The market research report predicts that the Global Genome Editing Market will grow at a CAGR of 14.4% during the forecast period.
The market has witnessed steady growth in the past few years with the development in technology and the introduction of highly sensitive, robust, and reliable systems in the market. The market is fueled due to increase in genetic disorders, increasing investment and funds, and technological advancements in genome editing.
The market continues to grow and is one of the increasingly accepted market in many countries worldwide. Vendors are focusing towards obtaining funds and collaborating with universities to enlarge their research and development capabilities. The majority of the revenue is generated from the leading players in the market with dominating sales of ThermoFisher Scientific, GenScript Corp., Sangamo Therapeutics, Lonza Group, and Horizon Discovery Group plc.
According to the analysis, North America accounted for the largest share of the global genome editing market in 2018. US dominates the market with majority of genome editing companies being located in this region. However, China has not been too far behind and has great government support for the research in genome editing field.
In 2018, the CRISPR segment occupied the largest share due to specific, effective, and cost-effective nature of the technology. Many companies are focusing on providing genome editing services. For instance, in January 2019, Horizon Discovery extended CRISPR screening service to primary human T cells.
- Cell Line Engineering
- Genetic Engineering
In 2018, the cell line engineering accounted the maximum share followed by genetic engineering. Increase in the number of people suffering with genetic disorders has driven the growth of the genome editing market.
By End Users:
- Research Institutes
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations
In 2018, the biotechnology and pharmaceutical companies gained the highest market share for genome editing market due to increased pervasiveness of cancer and infectious diseases are driving research goings-on in biotechnology & pharmaceutical companies segment.
- North America
The market is dominated by North America, followed by Asia Pacific and Europe. The major share of the North America market is from the US due to quick adoption of new and advanced technologies.
The market is extremely fragmented with several smaller companies struggling for market share. Big pharmaceutical establishments have also united with venture capitalists to provide funding to the start-ups. In 2015, Bayer financed $335 million and in the very same year, Celgene combined with Abingworth invested $64 million in CRISPR Therapeutics.
The NIH recently granted 21 somatic cell genome editing grants of almost $86 million over the next half a decade. These endowments are the foremost to be granted through the Somatic Cell Genome Editing (SCGE) program that was initiated in January 2018 with NIH Common Fund.
The companies are collaborating and licensing to increase their capabilities in the market. CRISPR, TALEN, ZFN, Meganuclease, ARCUS, and RTDS are some of the key technology areas concentrated by key players in the market. Since 2015, the deals on the CRISPR technology has drastically increased.
- ThermoFisher Scientific
- GenScript Corp.
- Sangamo Therapeutics
- Lonza Group
- Horizon Discovery Group plc
- Merck KGaA
- Transposagen Biopharmaceutical
- CRISPR Therapeutics
- Editas Medicine
- Integrated DNA Technologies
- New England Biolabs
- Origene Technologies, Inc.
Key Competitive Facts
Genetic editing technologies are intensely evolving from previous two decades and has facilitated in the variation of genome further rapidly and in a less expensive technique. The US is the leader in the CRISPR technology, while the market for TALEN genome editing technology is dominated by China.
- Understanding the potential market opportunity with precise market size and forecast data
- Detailed market analysis focusing on the growth of genome editing industry
- Factors influencing the growth of genome editing market
- In-depth competitive analysis of dominant and pureplay vendors
- Prediction analysis of genome editing market in both developed and developing regions
- Key insights related to major segments of the genome editing market
- Latest market trend analysis impacting the buying behavior of the consumers
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
1.2.1 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition
3.2 Segmented Addressable Market (SAM)
3.3 Industry Trends
3.4 Related Markets
3.4.1 Genetic Testing
18.104.22.168 Trends of the genetic testing market
3.4.2 Liquid Biopsy Market
22.214.171.124 Trends of Liquid biopsy market
3.4.3 Next-generation sequencing
126.96.36.199 Trends in the Next-generation sequencing market
4 Market Outlook
4.1 Funding Scenario
4.2 International Patent Classification (IPC) Codes and for the Technology Areas
4.2.1 Life Science Research
4.2.2 General Research
4.4 Porter 5 (Five) Forces
5 Market Characteristics
5.2 Market Segmentation
5.3 Market Dynamics
188.8.131.52 Increase in Genetic Disorders
184.108.40.206 Increasing Investment and Funds
220.127.116.11 Technological Advancements in Genome Editing
18.104.22.168 Ethical Concerns Associated to Genetic Editing
22.214.171.124 High Cost of Genome Engineering Technologies
126.96.36.199 Market Expansion Opportunities in Emerging Nations
188.8.131.52 Growing Collaboration for Genome Engineering Technologies
5.3.4 DRO - Impact Analysis
5.4 Key Stakeholders
6 Technology Types: Market Size and Analysis
6.2 CRISPR/Clustered Regularly Interspaced Short Palindromic Repeats
6.3 TALEN/Transcription Activator-Like Effector Nuclease
6.4 ZFN/Zinc-Finger Nucleases
7 Application Types: Market Size and Analysis
7.2 Cell Line Engineering
7.3 Genetic Engineering
8 End Users: Market Size and Analysis
8.2 Research Institutes
8.3 Biotechnology and Pharmaceutical Companies
8.4 Contract Research Organizations
9 Regions: Market Size and Analysis
9.2 North America
9.4 Asia Pacific
9.5 Rest of the World
10 Competitive Landscape
11 Vendors Profile
11.1 ThermoFisher Scientific, Inc.
11.1.2 Business Units
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 GenScript Corp.
11.3 Sangamo Therapeutics Inc.
11.4 Lonza Group
11.5 Horizon Discovery Group PLC
12 Companies to Watch For
12.1 Merck KGaA
12.2 Transposagen Biopharmaceuticals
12.3 CRISPR Therapeutics
12.4 Editas Medicine
12.5 Integrated DNA Technologies
12.6 New England Biolabs
12.7 Origene Technologies Inc.
For more information about this report visit https://www.researchandmarkets.com/research/jtfkdm/genome_editing?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005508/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/26/2019 07:46 AM/DISC: 03/26/2019 07:46 AM